Staging non-small cell lung cancer with whole-body PET.

PURPOSE To compare the accuracies of whole-body 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) and conventional imaging (thoracic computed tomography [CT], bone scintigraphy, and brain CT or magnetic resonance [MR] imaging) in staging bronchogenic carcinoma. MATERIALS AND METHODS Within 20 months, 100 patients with newly diagnosed bronchogenic carcinoma underwent whole-body FDG PET and chest CT. Ninety of these patients underwent radionuclide bone scintigraphy, and 70 patients underwent brain CT or MR imaging. For each patient, all examinations were completed within 1 month. A radiologic stage was assigned by using PET and conventional imaging independently and was compared with the pathologic stage. The accuracy, sensitivity, specificity, and negative and positive predictive values were calculated. RESULTS PET staging was accurate in 83 (83%) patients; conventional imaging staging was accurate in 65 (65%) patients (P < .005). Staging with mediastinal lymph nodes was correct by using PET in 67 (85%) patients and by using CT in 46 (58%) patients (P < .001). Nine (9%) patients had metastases demonstrated by using PET that were not found with conventional imaging, whereas 10 (10%) patients suspected of having metastases because of conventional imaging findings were correctly shown with PET to not have metastases. CONCLUSION Whole-body PET was more accurate than thoracic CT, bone scintigraphy, and brain CT or MR imaging in staging bronchogenic carcinoma.

[1]  E. van Marck,et al.  Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. , 1997, The European respiratory journal.

[2]  J. Doppman,et al.  Adrenal masses differentiated by MR. , 1986, Radiology.

[3]  C. Baamonde,et al.  Extrathoracic staging of bronchogenic carcinoma. , 1990, Chest.

[4]  L E Quint,et al.  Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. , 1996, AJR. American journal of roentgenology.

[5]  R. Ginsberg,et al.  Lung cancer staging: the value of ipsilateral scalene lymph node biopsy performed at mediastinoscopy , 1996 .

[6]  M P Sandler,et al.  Evaluation of benign vs malignant hepatic lesions with positron emission tomography. , 1998, Archives of surgery.

[7]  K. Yokoi,et al.  Brain metastasis in resected lung cancer: value of intensive follow-up with computed tomography. , 1996, The Annals of thoracic surgery.

[8]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[9]  P. Boccato,et al.  « Cyto-Assisted », Ultrasound-Guided Biopsy in the Diagnosis of Focal Disease of the Abdomen , 1991, Tumori.

[10]  R. Tarver,et al.  Cerebral metastases from lung carcinoma: neurological and CT correlation. Work in progress. , 1984, Radiology.

[11]  J. Wittenberg,et al.  Triangulation method for percutaneous needle guidance: the angled approach to upper abdominal masses. , 1981, AJR. American journal of roentgenology.

[12]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[13]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[14]  R. Hustinx,et al.  Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[16]  H. Abdel-Nabi,et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. , 1998, Radiology.

[17]  D. E. Jackson,et al.  Staging of non-small cell bronchogenic carcinoma. Relationship of the clinical evaluation to organ scans. , 1986, Chest.

[18]  J. Herndon,et al.  Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. , 1999, Radiology.

[19]  P. Valk,et al.  Cost-effectiveness of PET imaging in clinical oncology. , 1996, Nuclear medicine and biology.

[20]  T G Turkington,et al.  Performance characteristics of a whole-body PET scanner. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[22]  M. Maisey,et al.  FDG‐PET screening for cerebral metastases in patients with suspected malignancy , 1996, Nuclear medicine communications.

[23]  R. Hustinx,et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. , 1997, The European respiratory journal.

[24]  K. Yasumoto,et al.  Combined thoracoscopy and mediastinoscopy for mediastinal lymph node staging of lung cancer. , 1996, International surgery.

[25]  E. Kazerooni,et al.  Percutaneous CT‐Guided Biopsy of Adrenal Masses: Immediate and Delayed Complications , 1995, Journal of computer assisted tomography.

[26]  S S Gambhir,et al.  Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  P. Marsden,et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer , 1994, The Lancet.

[28]  G. Marchal,et al.  Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  V. M. Phillips,et al.  CT-guided adrenal biopsy: accuracy, safety, and indications. , 1985, AJR. American journal of roentgenology.

[31]  Current applications of imaging procedures in the patient with lung cancer. , 1991, International journal of radiation oncology, biology, physics.

[32]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[33]  J. Macfie,et al.  Diagnosis of abdominal masses with percutaneous biopsy guided by ultrasound. , 1990, BMJ.

[34]  M. Bernardino,et al.  Isolated adrenal masses in nonsmall-cell bronchogenic carcinoma. , 1984, Radiology.